Navigation Links
Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
Date:11/21/2007

REINACH, Switzerland, November 21 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today the results of a Phase I trial investigating the possible interaction between intravenous iclaprim and warfarin. Warfarin is widely used for the prophylaxis of thrombosis and embolism and its dosing needs to be well-controlled.The drug-drug interaction study comprised 24 healthy volunteers and was performed in Germany. Dosing of warfarin with and without pre- and co-administration of iclaprim (1.6 mg/kg infused over 60 minutes) was investigated.

Administration of intravenous iclaprim at this supra-therapeutic dose was assessed to be safe for clinical applications. It had no significant effect on the pharmakonetics and pharmacodynamics of warfarin. Moreover, the trial results again confirm the good safety and tolerability profile of iclaprim.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The results of this Phase I study are very positive, showing that iclaprim has no significant effect on the pharmacokinetics of warfarin, which is widely used in the targeted patient population. The results expand the experience gathered in an earlier Phase I study in which the interaction between ketaconazole and iclaprim was investigated. In summary, iclaprim's drug-drug interaction profile looks favourable. This is of great importance as iclaprim is expected to be administered to patients with significant co-morbidities and receiving several other medications. These Phase I data add substantial weight to the NDA package that we intend to file shortly with the U.S. Food and Drug Administration for intravenous iclaprim in its first indication: complicated Skin and Skins Structure Infections (cSSSI)."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of
'/>"/>

SOURCE Arpida Ltd.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Blood Donations in U.S. Testing Positive for Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Bellingham, WA (PRWEB) May 24, 2013 ... researchers, engineers, and industry suppliers will present technologies ... life at the annual SPIE Optics and ... August. Organized by SPIE, the international society ... the largest international, multidisciplinary optical sciences and technology ...
(Date:5/24/2013)... Many factors impact tissues targeting such ... transporters at the blood-tissue barrier. Even when tissue disposition ... in the tissue rather than the total tissue concentration. ... required to guide lead optimization, predict in vivo activity ... that may impact the likely human clinical dose. , ...
(Date:5/23/2013)... stopped breathing, his collapsed bronchus blocking the crucial flow ... watched helplessly, just praying that somehow the dire predictions ... had a good chance of not leaving the hospital ... Kaiba. "At that point, we were desperate. Anything that ... it." , They found hope at the University of ...
(Date:5/23/2013)... Patheon Inc ., a leading provider of ... industry, will host a complimentary webinar on “Cleaning Validation: ... June 4, 2013 at 11 a.m. Eastern Standard Time. ... with regulations for cleaning validation. Many companies have ... little evaluation of risk. Some companies have chosen ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... Biomarker Identification ... and ADME/Tox Applications, LINCOLN, R.I., ... into a worldwide,exclusive license and technology purchase agreement with Corning,Incorporated ... cell lines. Corning paid MultiCell a license fee, and ...
... of Unsaturated Fatty Acids in ... Cardiovascular ... AMRN ) today announced that it has initiated a cardiovascular,development ... acids in cardiovascular disease. Amarin plans to utilize,its extensive know-how ...
... Fourth Fourth Fiscal Fiscal ($ in millions) ... ... $364 $212 $2,807 $1,793 Soybean seed and traits ... Cotton seed and traits 58 52 319 ...
Cached Biology Technology:MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 2MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 3Amarin Announces Initiation of Cardiovascular Development Strategy 2Amarin Announces Initiation of Cardiovascular Development Strategy 3Amarin Announces Initiation of Cardiovascular Development Strategy 4Amarin Announces Initiation of Cardiovascular Development Strategy 5Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 2Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 3Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 4Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 5Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 6Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 7Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 8Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 9Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 10Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 11Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 12Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 13Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 14Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 15Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 16Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 17Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 18
(Date:5/22/2013)... a novel technique that can detect molecular variants in ... one of the most important, though time-consuming, processes in ... in Nature , post-doctoral researcher David Patterson, Professor ... the Center for Free-Electron Laser Science (CFEL) in Hamburg, ... fields to identify molecular variants apart, and to determine ...
(Date:5/22/2013)... 3 fatty acids in fish oil have long been ... the American Heart Association currently recommends eating at least ... rich in omega 3s. However, the mechanism behind this ... study, scientists led by Jason R. Carter of Michigan ... evidence that fish oil might specifically counteract the detrimental ...
(Date:5/22/2013)... and human health effects from disposal of millions ... scientists to recommend stronger government policies to encourage ... materials. That,s the conclusion of a new paper ... Technology . , Oladele A. Ogunseitan and colleagues ... for powering everything from smart phones to components ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3Fish oil may help the heart beat mental stress 2
... A new discovery about selective serotonin reuptake inhibitors ... treat mental health disorders like depression and anxiety, have ... published in the August 2010 issue of GENETICS ... identify secondary drug targets or pathways affected by SSRIs. ...
... Solitary snails in search of a mate put off parenthood as ... But when Physa acuta snails smell predators, they don,t ... parenthood much sooner than their calm counterparts, says a new study ... Durham, NC. "They can,t wait for a mate indefinitely ...
... Buck Institute for Age Research have successfully used human ... with Parkinson,s Disease (PD). The research, which validates ... developed, can be used to manufacture the type of ... way for the use of iPSC,s in various biomedical ...
Cached Biology News:SSRIs may pack more punch at the cellular level than believed 2Scared snails opt for single parenthood rather than wait for a mate 2Scientists successfully use human induced pluripotent stem cells to treat Parkinson's in rodents 2
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... synthase, cytoplasmic (C1-THF ... dehydrogenase (EC 1.5.1.5); ... 3.5.4.9); Formyltetrahydrofolate synthetase ... ...
Request Info...
Biology Products: